GENERAL ANNOUNCEMENT::BALLOTING RESULT UNDER PUBLIC OFFER OF RELATED PERSONS

Issuer & Securities

Issuer/Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

18-May-2018 17:38:03

Status

New

Announcement Sub Title

BALLOTING RESULT UNDER PUBLIC OFFER OF RELATED PERSONS

Announcement Reference

SG180518OTHRT1UT

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chariman and CEO

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This announcement has been prepared by the Company and its contents have been reviewed by DBS Bank Ltd. (the "Sponsor") for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact persons of the Sponsor are Heng Mui Mui, Managing Director and Kelvin Wong, Vice President at 12 Marina Boulevard Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone +65 6878 8888.

Attachments

<u>Hyphens%20Pharma%20International-</u> <u>Balloting%20Result%20of%20Related%20Persons 180518.pdf</u>



Hyphens Pharma International Limited

138 Joo Seng Road, 3rd Floor, Singapore 368361 T: (65) 6338 8551 F: (65) 6338 8825 W: www.hyphens.com.sg Co. Reg. No.: 201735688C

HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration Number: 201735688C) (Incorporated in the Republic of Singapore on 12 December 2017)

BALLOTING RESULT UNDER PUBLIC OFFER OF RELATED PERSONS

Capitalised terms used herein, unless otherwise defined, have the meanings ascribed to them in the offer document of Hyphens Pharma International Limited (the "Company") registered by the Singapore Exchange Securities Trading Limited (the "SGX-ST") (acting as agent on behalf of the Monetary Authority of Singapore) on 11 May 2018.

This announcement has been prepared by the Company and its contents have been reviewed by DBS Bank Ltd. (the "Sponsor") for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact persons of the Sponsor are Heng Mui Mui, Managing Director and Kelvin Wong, Vice President at 12 Marina Boulevard Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone +65 6878 8888.

Further to the announcement dated 17 May 2018 on, among other things, the basis of allotment for the Public Offer and disclosures pursuant to Rules 424 and 428 of the Rules of Catalist, the Company would like to inform that the associates (as such term is defined in the Rules of Catalist) of our Non-Executive Director and substantial shareholder, Dr. Tan Kia King, have not been allotted with Invitation Shares under the Public Offer.

Issued by DBS Bank Ltd.

For and on behalf of HYPHENS PHARMA INTERNATIONAL LIMITED

18 May 2018

IMPORTANT NOTICE

This announcement is for information purposes only and does not constitute or form part of an offer, invitation or solicitation of securities of the Company in Singapore or any other jurisdiction nor should it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The value of the Shares and the income derived from them may fall as well as rise. Shares are not obligations of, deposits in, or guaranteed by, the Company or the Sponsor, Issue Manager, Underwriter and Placement Agent or any of their respective affiliates. An investment in the Shares is subject to investment risks, including the possible loss of the principal amount invested. Listing of the Shares on the SGX-ST does not guarantee a liquid market for the Shares.

The Company was listed on the Catalist Board of the SGX-ST on 18 May 2018. The initial public offering of the Company was sponsored by DBS Bank Ltd.